Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Phase 2 Completed
17 enrolled 11 charts
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
Phase NA Completed
19 enrolled 7 charts
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Phase 2 Completed
102 enrolled 12 charts
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Phase NA Completed
13 enrolled 10 charts
HAITILS
Phase 1 Completed
8 enrolled
TIL
Phase 3 Completed
168 enrolled
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
Phase 1 Completed
18 enrolled
BaseTIL
Phase 1 Completed
9 enrolled
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase 1 Completed
Radiation and Combination Immunotherapy for Melanoma
Phase 2 Completed
4 enrolled 11 charts
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Completed
153 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
Vemurafenib and TIL Therapy for Metastatic Melanoma
Phase 1/2 Completed
13 enrolled 12 charts
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Phase 2 Completed
44 enrolled 11 charts
Peginterferon and TIL Therapy for Metastatic Melanoma
Phase 1/2 Completed
12 enrolled 10 charts
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Phase 1 Completed
6 enrolled
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Phase 1 Completed
20 enrolled
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
Phase 2 Completed
21 enrolled 12 charts
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
Phase 3 Completed
185 enrolled 11 charts
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
Phase 1/2 Completed
33 enrolled
TIL
Phase 3 Completed
70 enrolled
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Phase 1/2 Completed
10 enrolled
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
34 enrolled 11 charts
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Phase 2 Completed
4 enrolled 11 charts
T-cell Based Immunotherapy for of Melanoma
Phase 1/2 Completed
31 enrolled
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2
Phase 2 Completed
15 enrolled
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
Phase 1 Completed
12 enrolled
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
Phase 3 Completed
432 enrolled 7 charts
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
Phase 1 Completed
12 enrolled
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
Phase 2 Completed
19 enrolled
BBI
Phase 1/2 Completed
24 enrolled
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Phase 2 Completed
158 enrolled 14 charts
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
20 enrolled 9 charts
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
Phase 2 Completed
50 enrolled
BCAA
Phase 1 Completed
10 enrolled
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Phase 2 Completed
24 enrolled 11 charts
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase 2 Completed
170 enrolled 23 charts
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
Phase 2 Completed
8 enrolled 8 charts
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Phase 2 Completed
138 enrolled 16 charts
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Phase 2 Completed
58 enrolled
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
Phase 1 Completed
11 enrolled
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
Phase 3 Completed
140 enrolled
Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases
Phase 2 Completed
51 enrolled
Dendritic Cell Based Therapy of Malignant Melanoma
Phase 1/2 Completed
25 enrolled
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
Phase 2 Completed
141 enrolled